The results showed that the level of AKT1 and mTOR protein in all 5 thymoma patients who received DXMS treatment was lower than that in the non-DXMS group (Fig. 7A), while the level of apoptosis protein, cleaved caspase-3, showed the opposite trend (Fig. 7B). This evidence concerns the gene AKT1 and thymoma.